全文获取类型
收费全文 | 4873篇 |
免费 | 294篇 |
国内免费 | 38篇 |
专业分类
耳鼻咽喉 | 125篇 |
儿科学 | 80篇 |
妇产科学 | 58篇 |
基础医学 | 801篇 |
口腔科学 | 101篇 |
临床医学 | 359篇 |
内科学 | 1118篇 |
皮肤病学 | 110篇 |
神经病学 | 203篇 |
特种医学 | 146篇 |
外科学 | 865篇 |
综合类 | 19篇 |
预防医学 | 133篇 |
眼科学 | 213篇 |
药学 | 333篇 |
中国医学 | 5篇 |
肿瘤学 | 536篇 |
出版年
2023年 | 35篇 |
2022年 | 66篇 |
2021年 | 97篇 |
2020年 | 39篇 |
2019年 | 83篇 |
2018年 | 107篇 |
2017年 | 80篇 |
2016年 | 106篇 |
2015年 | 109篇 |
2014年 | 126篇 |
2013年 | 150篇 |
2012年 | 219篇 |
2011年 | 250篇 |
2010年 | 151篇 |
2009年 | 106篇 |
2008年 | 211篇 |
2007年 | 246篇 |
2006年 | 238篇 |
2005年 | 246篇 |
2004年 | 222篇 |
2003年 | 220篇 |
2002年 | 232篇 |
2001年 | 222篇 |
2000年 | 176篇 |
1999年 | 164篇 |
1998年 | 72篇 |
1997年 | 64篇 |
1996年 | 69篇 |
1995年 | 34篇 |
1994年 | 32篇 |
1993年 | 35篇 |
1992年 | 120篇 |
1991年 | 103篇 |
1990年 | 76篇 |
1989年 | 83篇 |
1988年 | 60篇 |
1987年 | 76篇 |
1986年 | 77篇 |
1985年 | 54篇 |
1984年 | 50篇 |
1983年 | 37篇 |
1982年 | 16篇 |
1981年 | 16篇 |
1980年 | 18篇 |
1979年 | 38篇 |
1978年 | 15篇 |
1977年 | 27篇 |
1976年 | 21篇 |
1968年 | 26篇 |
1967年 | 13篇 |
排序方式: 共有5205条查询结果,搜索用时 15 毫秒
941.
Yoshiaki Katada Mayumi Yasumoto Chikako Ishii Hiroshi Tanaka Kazuya Nakamoto Isamu Ohashi Miwako Nozaki 《European radiology》2010,20(9):2241-2247
Objective
To evaluate the additional value of inversion recovery (IR) single-shot turbo spin-echo (SSTSE) imaging with sensitivity encoding (SENSE) using the inversion time (TI) value of hepatic haemangioma as a supplement to conventional T2-weighted turbo spin-echo (TSE) imaging for the discrimination of hepatic haemangiomas and cysts.Methods
A total of 134 lesions (77 hepatic haemangiomas, 57 hepatic cysts) in 59 patients were evaluated. Three readers evaluated these images and used a five-point scale to evaluate the lesion status. A receiver operating characteristic (ROC) analysis and 2?×?2 table analysis were used.Results
The ROC analysis for all the readers and all the cases revealed a significantly higher area under the curve (AUC) for the combination of moderately and heavily T2-weighted TSE with IR-SSTSE images (0.945) than for moderately and heavily T2-weighted TSE images alone (0.894) (P?<?0.001). For the combination of T2-weighted TSE with IR-SSTSE versus T2-weighted TSE alone, the 2?×?2 table analysis revealed a higher true-positive rate; this difference was statistically significant (P?<?0.0001).Conclusion
The introduction of IR-SSTSE with SENSE sequences significantly improves the diagnostic accuracy of the differentiation of hepatic haemangioma and cysts while increasing the time required for routine abdominal imaging by only 20 s. 相似文献942.
Sanuki-Fujimoto N Takeda A Ohashi T Kunieda E Iwabuchi S Takatsuka K Koike N Shigematsu N 《The British journal of radiology》2010,83(996):1063-1071
This study aimed to assess the imaging appearances of focal liver reactions following stereotactic body radiotherapy (SBRT) for small hepatocellular carcinoma (HCC) and to examine relationships between imaging appearance and baseline liver function. We retrospectively studied 50 lesions in 47 patients treated with SBRT (30-40 Gy in 5 fractions) for HCC, who were followed up for more than 6 months. After SBRT, all patients underwent regular follow-ups with blood tests and dynamic CT scans. At a median follow-up of 18.1 months (range 6.2-43.7 months), all lesions but one were controlled. 3 density patterns describing focal normal liver reactions around HCC tumours were identified in pre-contrast, arterial and portal-venous phase scans: iso/iso/iso in 4 patients (Type A), low/iso/iso in 8 patients (Type B) and low/iso (or high)/high in 38 patients (Type C). Imaging changes in the normal liver surrounding the treated HCC began at a median of 3 months after SBRT, peaked at a median of 6 months and disappeared 9 months later. Liver function, as assessed by the Child-Pugh classification, was the only factor that differed significantly between reactions to treatment showing "non-enhanced" (Type A and B) and "enhanced" (Type C) appearances in CT. Hence, liver tissue with preserved function is more likely to be well enhanced in the delayed phase of a dynamic contrast-enhanced CT scan. The CT appearances of normal liver seen in reaction to the treatment of an HCC by SBRT were therefore related to background liver function and should not be misread as recurrence of HCC. 相似文献
943.
944.
Kenichi Inoue Kazuhiko Nakagami Mitsuhiro Mizutani Yasuo Hozumi Yasuhiro Fujiwara Norikazu Masuda Fumine Tsukamoto Mitsue Saito Shigeto Miura Kenji Eguchi Tetsu Shinkai Masashi Ando Toru Watanabe Noriyuki Masuda Yasuo Ohashi Muneaki Sano Shinzaburo Noguchi 《Breast cancer research and treatment》2010,119(1):127-136
We evaluated the efficacy and safety of sequential therapy with trastuzumab monotherapy (H-mono) followed by H plus docetaxel (D) after disease progression (H → H + D) versus combination therapy with H + D as first-line therapy. Patients with human epidermal growth factor receptor type 2 (HER2)-positive metastatic breast cancer (MBC) and left ventricular ejection fraction >50% were randomly assigned to either (a) H → H + D [H, once weekly 2 mg/kg (loading dose, 4 mg/kg); D, once every 3 weeks 60 mg/m2] or (b) H + D. Primary endpoints were progression-free survival (PFS) for the H-mono stage of the H → H + D group and H + D group and overall survival (OS) for both groups. Secondary endpoints were overall response rate, time to treatment failure, second PFS and safety. The planned number of patients was 160 patients in total. Of 112 patients enrolled, 107 were eligible. After 112 patients were enrolled, the Independent Data Monitoring Committee recommended stopping enrollment because PFS and OS were greater in the H + D group than the H → H + D group. Median PFS was 445 days in the H + D group versus 114 days for H-mono in the H → H + D group [hazard ratio (HR), 4.24; P < 0.01]. OS was significantly longer in the H + D group (HR, 2.72; P = 0.04). H + D therapy is significantly superior to H → H + D therapy as first-line therapy in patients with HER2-positive MBC, especially in terms of OS. 相似文献
945.
Hirotaka Fukasawa Tatsuo Yamamoto Yoshihide Fujigaki Taro Misaki Naro Ohashi Tatsuya Takayama Sayuri Suzuki Soichi Mugiya Toshiaki Oda Chiharu Uchida Kyoko Kitagawa Takayuki Hattori Hidetoshi Hayashi Seiichiro Ozono Masatoshi Kitagawa Akira Hishida 《International journal of cancer. Journal international du cancer》2010,127(7):1517-1525
946.
Naruto Taira Masataka Sawaki Miyako Takahashi Kojiro Shimozuma Yasuo Ohashi 《Breast cancer (Tokyo, Japan)》2010,17(3):183-189
Treatment of elderly patients with breast cancer is limited by the lack of evidence-based medicine due to exclusion of elderly
persons from clinical studies and the difficulty of decision-making in an elderly population comprising subjects with heterogeneous
health backgrounds. Individual variation of health conditions is larger in elderly patients than in young people. Since the
risk–benefit balance of treatment depends on the health background, judgment of the vulnerability of individual patients is
required in treatment planning. The comprehensive geriatric assessment (CGA) is a tool for acquisition of information for
design of a cancer treatment plan based on evaluation of the vulnerability of elderly patients from various perspectives.
The domains of the CGA include physical function, comorbidity, cognitive function, psychological status, social support system,
nutrition, and medication. The CGA can be used to predict survival and adverse events; to identify health problems that cannot
be detected based on medical history or examination; to recognize new problems that emerge during course observation; and
to improve psychological conditions. However, application of the CGA in routine clinical practice requires establishment of
a consensus regarding the survey method, evaluation scale, and use of results in decision-making. A prospective investigation
of the CGA as an outcome index in elderly breast cancer patients is required to address these issues. 相似文献
947.
Morihiko Kimura Takeshi Tominaga Yuichi Takatsuka Masakazu Toi Rikiya Abe Hiroki Koyama Shigemitsu Takashima Yasuo Nomura Shigeto Miura Izo Kimijima Hideya Tashiro Yasuo Ohashi 《Breast cancer (Tokyo, Japan)》2010,17(3):190-198
Background
To compare the cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy and the anthracycline-containing regimen cyclophosphamide, epirubicin, and fluorouracil (CEF) to evaluate the efficacy and safety of the latter.Methods
A total of 294 patients with axillary node-positive primary breast cancer of STAGE I–IIIa were randomly assigned to either CEF [cyclophosphamide (CPA) 500 mg/m2 i.v. days 1 and 8; epirubicin (EPI) 60 mg/m2 i.v. day 1; and 5-fluorouracil (5-FU) 500 mg/m2 i.v. days 1 and 8] or CMF [CPA 500 mg/m2 i.v. days 1 and 8; methotrexate (MTX) 40 mg/m2 i.v. days 1 and 8; and 5-FU 500 mg/m2 i.v. days 1 and 8]. Both treatment regimens were comprised of six cycles at 4-week intervals. Tamoxifen (TAM) 20 mg/day was concomitantly given to estrogen receptor (ER)-positive patients and those with undetermined ER status for 2 years.Results
The overall 5-year survival was 77.1% for CEF and 71.4% for CMF [p = 0.24; hazard ratio 0.79 (95% CI 0.50–1.24)], and the 5-year disease-free survival was 55.7% for CEF and 48.9% for CMF [p = 0.15; hazard ratio 0.80 (95% CI 0.57–1.12)]. Although the log-rank test did not show a significant difference, both overall and disease-free survivals were higher for CEF according to the point estimates. Adverse drug reactions (ADRs) occurred more frequently in CEF.Conclusion
Whereas CEF had a good trend compare with CMF, it could not be proven statistically significant. The principal cause of the failure seems to be insufficient power, that is, the dose intensity (EPI: 60 mg/m2) set 10 years ago, when the trial began, was low, and the number of trial subjects was small because of the background of the times, which made the accumulation of cases extremely difficult. However, the trial should be considered to be meaningful, as it was the first, formally conducted controlled trial on chemotherapy in Japan. 相似文献948.
Tobinai K Ogura M Itoh K Kinoshita T Hotta T Watanabe T Morishima Y Igarashi T Terauchi T Ohashi Y;All Collaborators of the IDEC-CB Study Group in Japan 《Cancer science》2010,101(12):2579-2585
Rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) is one of the most frequently applied initial treatments for indolent B-cell non-Hodgkin lymphoma (B-NHL); however, information on its long-term outcome is limited. Untreated patients in the concurrent arm (Arm C) received six R (375 mg/m(2) ) treatments, 2 days prior to each cycle of CHOP, and patients in the sequential arm (Arm S) received 6 weekly R (375 mg/m(2) ) treatments following six cycles of CHOP. Sixty-nine patients were randomized but two patients were withdrawn before receiving the protocol treatment. Sixty-five patients (94%) had follicular lymphoma, and 37 (55%) were at low risk, 23 (34%) at intermediate risk and seven (10%) at high risk according to the Follicular Lymphoma International Prognostic Index. We previously reported that the overall response rate (ORR) in Arm C and in Arm S was 94% and 97%, respectively. The median progression-free survival (PFS)/7-year PFS rate in Arm C, Arm S and all 67 assessable patients was 2.4 years/23% (95% confidence interval [CI], 9-40%), 3.8 years/41% (95% CI, 23-57%) and 2.8 years/32% (95% CI, 20-45%), respectively. There was no significant difference between the two arms (P = 0.107). The overall survival (OS) of the 67 patients was 95% at 7 years. In conclusion, R-CHOP is a highly effective initial treatment for untreated indolent B-NHL in terms of ORR and OS; however, its long-term PFS is not good enough either in concurrent or sequential combination, warranting further investigations on post-remission therapy. 相似文献
949.
Viral protein U(Vpu) is an accessory protein associated with two main functions important in human immunodeficiency virus type 1(HIV-1) replication and dissemination; these are down-regulation of CD4 receptor through mediating its proteasomal degradation and enhancement of virion release by antagonizing tetherin/BST2. It is also well established that Vpu is one of the most highly variable proteins in the HIV-1 proteome. However it is still unclear what drives Vpu sequence variability, whether Vpu acquires polymorphisms as a means of immune escape, functional advantage, or otherwise. It is assumed that the host-pathogen interaction is a cause of polymorphic phenotype of Vpu and that the resulting functional heterogeneity of Vpu may have critical significance in vivo. In order to comprehensively understand Vpu variability, it is important to integrate at the population level the genetic associationapproaches to identify specific amino acid residues and the immune escape kinetics which may impose Vpu functional constraints in vivo. This review will focus on HIV-1 accessory protein Vpu in the context of its sequence variability at population level and also bring forward evidence on the role of the host immune responses in driving Vpu sequence variability; we will also highlight the recent findings that illustrate Vpu functional implication in HIV-1 pathogenesis. 相似文献
950.
Marie Hanaoka Masaji Hashimoto Kazunari Sasaki Masamichi Matsuda Takeshi Fujii Kenichi Ohashi Goro Watanabe 《World journal of gastroenterology : WJG》2013,19(28):4624-4629
A retroperitoneal hemangioma is a rare disease. We report on the diagnosis and treatment of a retroperitoneal hemangioma which had uncommonly invaded into both the pancreas and duodenum, thus requiring a pylorus preserving pancreaticoduodenectomy (PpPD). A 36-year-old man presented to our hospital with abdominal pain. An enhanced computed tomography scan without contrast enhancement revealed a 12 cm × 9 cm mass between the pancreas head and right kidney. Given the high rate of malignancy associated with retroperitoneal tumors, surgical resection was performed. Intraoperatively, the tumor was inseparable from both the duodenum and pancreas and PpPD was performed due to the invasive behavior. Although malignancy was suspected, pathological diagnosis identified the tumor as a retroperitoneal cavernous hemangioma for which surgical resection was the proper diagnostic and therapeutic procedure. Reteoperitoneal cavernous hemangioma is unique in that it is typically separated from the surrounding organs. However, clinicians need to be aware of the possibility of a case, such as this, which has invaded into the surrounding organs despite its benign etiology. From this case, we recommend that combined resection of inseparable organs should be performed if the mass has invaded into other tissues due to the hazardous nature of local recurrence. In summary, this report is the first to describe a case of retroperitoneal hemangioma that had uniquely invaded into surrounding organs and was treated with PpPD. 相似文献